Health
Emyria and partner Mind Medicine Australia launch psychedelic-assisted therapy program targeting PTSD – Proactive Investors Australia
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS).
EMDMA-001 has been modelled on a major Phase III clinical trial developed by the Multidisciplinary Association for Psychedelic Studies (MAPS). Emyria Ltd (ASX:EMD) and partner Mind Medicine Australia have launched the EMDMA-001 psychedelic-assisted therapy program targeting sufferers of treatment-resistant post-traumatic stress disorder (PTSD).
As a first step, and pending ethics approval, Emyria, an innovative drug development and clinical services company, will sponsor a major, independently monitored,…
-
Noosa News17 hours agoWest Coast Eagles draftee Josh Lindsay wants to carry on Troy Selwood’s legacy
-
Noosa News22 hours agoDoorDash offering Aussies free burgers, burritos, pizzas and meal bundles as an end of year treat
-
General18 hours agoLabor to squeeze public service, sparking warnings of job losses
-
General21 hours agoSister Kate’s site to become home to Perth’s first Aboriginal aged care facility